Abstract

Roopa S.* and Fmith Celvia Miranda

ABSTRACT

Transdermal drug delivery systems (TDDS), which are self-administrable and non-invasive, can improve bioavailability and patient compliance by bypassing first-pass metabolism. Transdermal novel drug delivery has various benefits over traditional delivery methods. However, physicochemical characteristics of numerous drugs make them less soluble when given topically. Enhancement of penetration of both low as well as high molecular weight drugs is the principle endeavour in designing these vesicles. Vesicular-based TDDS have attracted a lot of significant interest in recent years because they're designed for controlled, efficient, and targeted drug delivery. One of these delivery technologies, transferosomal-based formulations, has grown in popularity due to its ability to achieve all of the desired criteria and qualities. Transferosomes combine the characteristics of liposomes and niosomes because they contain both liposomes (phospholipids and cholesterols) and niosomes as components (nonionic surfactants; edge activators), as a result, they are referred to as the first generation of elastic liposomes. However transdermal drug delivery is difficult due to the presence of the skin's protective barrier. Transferosomal drug delivery overcomes all obstacles due to its unique characteristics, such as its ultra-deformable vesicular nature. The benefits, limitations, modes of penetration, formulations, production and assessment methodologies, and pharmaceutical uses of transferosomal drug delivery systems are discussed in this paper.